Today my and Scott’s preceptees presented their first journal club to the group at VGH. The two student critically appraised an RCT assessing the efficacy of vortioxetine in improving cognitive function in major depressive disorder (MDD) !independently of the antidepressant effects. We had coached them in anticipation of questions that may be asked and they appeared well prepared. I believe it may have been more anxiety provoking for myself than the student. Perhaps it was because it was no longer in my control or maybe because I recalled being nervous for my journal club. Nonetheless, they did well and I was afforded an opportunity to provide direct feedback. Providing feedback is a skill in itself and I was relieved that it was well received. The main constructive criticism was slightly ironic as it is a concept I continue to grapple with: trust yourself and be confident when you know the answer to a question. Below is the result of their (and our) hard work.
Additional information for all of the pharmanerds out there: just the week prior to their presentation, the FDA rejected the expanded claim of vortioxetine as a cognitive enhancer in MDD based on this and the FOCUS trial. Hot of the press!